Skip to content

ArriVent BioPharma, Inc. AVBP Operating Lease Liabilities

Operating Lease Liabilities at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$3.5M-40.8%
Nuvation Bio logo
Nuvation BioNUVB
$2.2M-42.7%
Immunome logo
ImmunomeIMNM
$3.69M-22.6%
Erasca, Inc. logo
Erasca, Inc.ERAS
$40.7M-11.6%
Bicara Therapeutics logo
Bicara TherapeuticsBCAX
$301K
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$14.22M+189%

Other financials

Income statement

See full
Operating income-$46.1M+30.9%
Net income-$43.3M+32.7%
EPS (diluted)-$0.96+49.5%

Balance sheet

See full
Cash & equivalents$62.1M+24.5%
Total debt$419.0K+204%
Total equity$324.0M+60.0%
Total assets$349.3M+62.1%

Cash flow

See full
Operating cash flow-$41.9M+38.4%

Valuation

See full
Market cap$1.49B+62.1%
Enterprise value$1.43B+65.4%

Returns & leverage

See full
Return on equity-55.2%+8.0pp
Debt / equity0.0×
Current ratio14×-0.4×

Where this comes from

Reported directly by ArriVent BioPharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about ArriVent BioPharma, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ArriVent BioPharma, Inc.'s operating lease liabilities?
ArriVent BioPharma, Inc. (AVBP) reported operating lease liabilities of $320K in Q1 2026.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.